S 3267119th CongressIn Committee
ASAP Act
Standard Summary
Balanced plain-English summary
This bill amends Medicare law to cover blood-based and other approved early detection screening tests for Alzheimer's disease and related dementias beginning in 2028, and it establishes payment rules for those tests under Medicare Part B.
Key Points
- 1Adds Medicare coverage for Alzheimer's disease and related dementias early detection screening tests.
- 2Defines qualifying tests as FDA-cleared, classified, or approved blood or biospecimen tests.
- 3Includes genomic sequencing blood tests and equivalent tests such as cell-free nucleic acid tests, multiplex panels, whole genome sequencing, protein expression tests, and medical imaging.
- 4Sets the coverage start date at January 1, 2028.
- 5Amends Medicare payment rules to include these screening tests.
Impact Areas
Medicare beneficiariesOlder adultsPeople at risk of dementiaTest developers and laboratoriesPhysicians and healthcare providers
Generated by deepseek/deepseek-v4.1-flash-1017Nov 18, 2026